Definium Therapeutics to Present Phase 3 Trial Outcomes for Depression Drug

Definium Therapeutics announced plans to host a webcast to discuss the initial results from its Phase 3 Emerge study. The study evaluated the effectiveness of a single dose of DT120 ODT for adults suffering from major depressive disorder. This presentation will provide key insights into the drug's performance against a placebo.